Taking people in ChinaNo phase

Imaging Test Targeting MSLN Protein in Ovarian, Lung and Pancreatic Cancer

Tests a special scan agent that finds MSLN-expressing tumors in adults with cancer.

Key facts

Who runs it: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Where: Wuhan, ChinaSee the site
Trial code: NCT06843629
Registry title: Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Status: Recruiting
People taking part: 100 people, planned
Started: 1 Oct 2024
Expected to end: 30 Jun 2028
Type of study: Observational
Treatments tested: Specific positron imaging agents targeting MSLN
Record updated: 28 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with suspected or confirmed pancreatic cancer, ovarian cancer or lung adenocarcinoma, and for healthy volunteers. It tests a PET scan agent aimed at MSLN.

Age: 18 to 65 years
Sex: Women and men can both join.
Disease stage: Suspected or confirmed malignant tumour such as pancreatic cancer, ovarian cancer or lung adenocarcinoma, in good general condition.
Biomarker or test result: The tumours are described as having high MSLN expression.

Main reasons for not taking part

Cannot complete a PET/MR or PET/CT scan (for example cannot lie down, fear of closed spaces or radiation)
Known allergy to the MSLN antibody fragment imaging agent or its added ingredients
Fasting blood glucose above 11.0 mmol/L (198 mg/dL) before the 18F-FDG injection
Pregnant or breastfeeding
Other illnesses or poor compliance in the investigator's view

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

Each subject must meet all enrollment criteria to be eligible to participate in the study:; The subject or his/her legal representative is able to sign and date the informed consent form; A commitment to comply with the research procedures and to cooperate in the implementation of the full research process; Adult patients or healthy volunteers (aged 18 or above) of either sex; Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition; Consistent with the results of specific laboratory tests; Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；; Other set entry criteria

Who cannot take part

All subjects who meet any of the exclusion criteria baseline will be excluded from the study:; Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.); Having other comorbidities; Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection；; Have a history of comorbid drug use; Patients considered by the investigator to have poor compliance; Patients during pregnancy or lactation; Persons with other factors that make participation in this test inappropriate

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 65 years old?

Where in China

Wuhan Union Hospital, ChinaWuhan, ChinaContact: Xiaoli Lan, PhDTaking people

About the trial

What the trial wants to find out

The project aims to perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using targeted MSLN-specific imaging agents (taking [68Ga]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with [18F]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.